title: Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer.
abstract: The prognostic value of EGF-R, IGF-1-R and SS-R, and of cytosolic estrogen-regulated pS2 protein, was studied in patients (pts) with primary breast and advanced ovarian cancer. Ovarian cancer tissues were negative for pS2 (by immunoradiometric assay) IGF-1-R and EGF-R contents (by ligand binding assay, LBA) were of no or moderate prognostic value for breast cancer pts (n = 214). For advanced ovarian cancer pts, EGF-R content determined by LBA (n = 55) showed no prognostic value, whereas EGF-R status (n = 35) determined by immunohistochemistry (MoAb 2E9) significantly correlated with progression of disease (P less than 0.05). In breast cancer pts, both SS-R and pS2 showed no association with tumor size, nodal status and grade. For pS2 the best cut-off level with respect to relapse-free (RFS) and overall survival (OS) was found to be 11 ng/mg protein. Both SS-R (1 g% SS-R+, n = 135; P less than 0.04) and pS2 (27% pS2+, n = 197; P less than 0.001), which were mainly positive in ER+ tumors, were of prognostic value, especially within the subgroups with ER+/PgR+ tumors. Also within N+ and No pts the 5-yr RFS and OS showed a difference between pS2+ and pS2- (33 and 54% for N+, and 31 and 13% difference for No pts). In summary, SS-R and pS2 are valuable prognosticators in breast cancer pts, and prognostic significance of EGF-R in ovarian cancer pts needs further study.
authors.affiliation: Division of Endocrine Oncology, Biochemistry and Clinical Endocrinology, Dr. Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
authors.forename: J A
authors.initials: JA
authors.lastname: Foekens
authors.forename: W L
authors.initials: WL
authors.lastname: van Putten
authors.forename: H
authors.initials: H
authors.lastname: Portengen
authors.forename: C J
authors.initials: CJ
authors.lastname: Rodenburg
authors.forename: J C
authors.initials: JC
authors.lastname: Reubi
authors.forename: P M
authors.initials: PM
authors.lastname: Berns
authors.forename: S C
authors.initials: SC
authors.lastname: Henzen-Logmans
authors.forename: M E
authors.initials: ME
authors.lastname: van der Burg
authors.forename: J
authors.initials: J
authors.lastname: Alexieva-Figusch
authors.forename: J G
authors.initials: JG
authors.lastname: Klijn
mesh_terms: D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000175:diagnosis / Q000378:metabolism*; D066246:ErbB Receptors / Q000378:metabolism*; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D009363:Neoplasm Proteins / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000378:metabolism*; D011379:Prognosis; D011506:Proteins; D011956:Receptors, Cell Surface / Q000378:metabolism; D017451:Receptors, Somatomedin; D000071163:Trefoil Factor-1; D025521:Tumor Suppressor Proteins
chemical_list: D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D011506:Proteins; D011956:Receptors, Cell Surface; D017451:Receptors, Somatomedin; C051838:TFF1 protein, human; D000071163:Trefoil Factor-1; D025521:Tumor Suppressor Proteins; D007334:Insulin-Like Growth Factor I; D066246:ErbB Receptors